1,651 Shares of Regeneron Pharmaceuticals, Inc. $REGN Purchased by Milestone Asset Management LLC

Key Points

• Milestone Asset Management purchased 1,651 Regeneron shares worth approximately $1.25 million, while institutional investors collectively own 83.31% of REGN.
• Regeneron reported quarterly earnings of $14.29 per share and revenue of $4.29 billion, beating analyst estimates; revenue increased 16.7% year over year.
• Analysts maintain a generally positive outlook, with REGN carrying a “Moderate Buy” consensus rating and an average price target of $845.21, while recent insider sales occurred under pre-arranged Rule 10b5-1 plans.

Milestone Asset Management LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,651 shares of the biopharmaceutical company's stock, valued at approximately $1,252,000.

Several other institutional investors also recently bought and sold shares of REGN. Western Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals in the first quarter worth about $26,000. SHP Wealth Management purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $26,000. Armstrong Advisory Group Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 466.7% during the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 28 shares during the last quarter. Activest Wealth Management increased its position in shares of Regeneron Pharmaceuticals by 780.0% during the third quarter. Activest Wealth Management now owns 44 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 39 shares in the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $29,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In other news, EVP Marion Mccourt sold 1,131 shares of the stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total transaction of $969,708.09. Following the transaction, the executive vice president directly owned 12,003 shares of the company's stock, valued at $10,291,252.17. This represents a 8.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the transaction, the director directly owned 603 shares in the company, valued at $512,550. The trade was a 39.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,093 shares of company stock valued at $6,506,845 in the last quarter. 6.97% of the stock is currently owned by corporate insiders.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: UBS upgraded Regeneron to “Buy” and raised its price target to $978 from $660, arguing that the market is underestimating the long-term opportunity for Dupixent. The new target implies substantial upside and is the clearest near-term catalyst for investor optimism. Tickerreport UBS upgrade article
• Positive Sentiment: A valuation analysis says Regeneron still appears below fair value after fresh trial data and renewed attention on its immunology alliance. The report suggests the company’s earnings power may not be fully reflected in its current valuation. Regeneron stock fair value article
• Positive Sentiment: Regeneron could benefit from having paid off its balance owed to Sanofi, which had reduced the revenue reported from their partnership. The change may improve the financial contribution from the collaboration going forward. Trefis Regeneron catalysts article
• Positive Sentiment: Analysts expect double-digit bottom-line growth in the upcoming third-quarter report, keeping earnings momentum and the company’s ability to exceed estimates in focus. Barchart Regeneron earnings preview
• Neutral Sentiment: A review of biotechnology-sector results included Regeneron among the companies investors are evaluating, but provided limited new company-specific information. Yahoo Finance biotechnology earnings review
• Negative Sentiment: Director Andrew Murphy sold 4,147 shares worth approximately $3.2 million under a pre-arranged Rule 10b5-1 plan. Because the sale was scheduled in advance, it is a limited bearish signal, although it may weigh modestly on sentiment.

Regeneron Pharmaceuticals Stock Up 2.3%

REGN opened at $796.34 on Friday. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The firm has a 50 day moving average price of $791.59 and a 200-day moving average price of $721.30. Regeneron Pharmaceuticals, Inc. has a twelve month low of $564.00 and a twelve month high of $859.34. The stock has a market capitalization of $81.99 billion, a price-to-earnings ratio of 19.68, a PEG ratio of 1.35 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts' consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. During the same quarter in the prior year, the firm earned $12.81 earnings per share. The firm's revenue for the quarter was up 16.7% compared to the same quarter last year. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 47.93 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were paid a dividend of $0.94 per share. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals's payout ratio is currently 9.29%.

Wall Street Analyst Weigh In

REGN has been the topic of several analyst reports. Wells Fargo & Company upped their price objective on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an "equal weight" rating in a research report on Friday, July 31st. The Goldman Sachs Group lifted their target price on Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the stock a "buy" rating in a report on Friday, July 31st. Evercore boosted their price target on Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the stock an "outperform" rating in a research note on Friday, July 31st. JPMorgan Chase & Co. boosted their price target on Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the stock an "overweight" rating in a research note on Tuesday, October 6th. Finally, Royal Bank Of Canada upped their price target on Regeneron Pharmaceuticals from $737.00 to $810.00 and gave the company a "sector perform" rating in a report on Thursday, October 8th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $845.21.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron's marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.